Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

about

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

Item

http://www.wikidata.org/entity/Q47425091

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@en

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@nl

type

Item

label

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@en

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@nl

prefLabel

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@en

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@nl

P1476

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.

@en

P2093

Edmund Feng Tian

http://www.w3.org/2001/XMLSchema#string

Hong Wang

http://www.w3.org/2001/XMLSchema#string

Kok-Onn Lee

http://www.w3.org/2001/XMLSchema#string

Meng-Kwoon Sim

http://www.w3.org/2001/XMLSchema#string

Yiong-Huak Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps

Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases

Des-Aspartate-Angiotensin I Attenuates Mortality of Mice Exposed to Gamma Radiation via a Novel Mechanism of Action

A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects

Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development.

Peptide therapeutics: current status and future directions.

Des-aspartate-angiotensin I, a novel angiotensin AT(1) receptor drug.

Formation of angiotensin III from [des-Asp1]angiotensin I in the mesentric vasculature.

In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III.

Des-aspartate-angiotensin I causes specific release of PGE2 and PGI2 in HUVEC via the angiotensin AT1 receptor and biased agonism.

P304

51-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-017-0218-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Martin Hui Cai

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29168127

http://www.w3.org/2001/XMLSchema#string

P921

human subject research

P932

5833902

http://www.w3.org/2001/XMLSchema#string